CSL Limited (CSLLY)
OTHER OTC:CSLLY
CSLLY Stock Chart & Stats
$58.43
$0.39(0.44%)
At close: 4:00 PM EST
$58.43
$0.39(0.44%)
Day’s Range― - ―
52-Week Range$23.68 - $44.53
Previous CloseN/A
Volume10.38K
Average Volume (3M)1.91K
Market Cap
$47.50B
Enterprise Value$59.36B
Total Cash (Recent Filing)$1.15B
Total Debt (Recent Filing)$12.57B
Price to Earnings (P/E)69.3
Beta0.41
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.33%
Share Statistics
EPS (TTM)0.21
Shares Outstanding1,941,275,900
10 Day Avg. Volume0
30 Day Avg. Volume1,912
Financial Highlights & Ratios
PEG Ratio3.83
Price to Book (P/B)7.93
Price to Sales (P/S)9.94
P/FCF Ratio60.28
Enterprise Value/Market Cap1.25
Enterprise Value/Revenue3.82
Enterprise Value/Gross Profit7.85
Enterprise Value/Ebitda11.65
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationCSL's recently reported 35.6% free cash flow growth and high cash conversion ratios indicate durable internal funding. Robust FCF supports ongoing R&D, capex, and expanded buybacks/dividends while providing a buffer for reinvestment and strategic flexibility over the next 2–6 months.
Diversified Portfolio And Successful Specialty LaunchesCSL's mix of plasma therapies, vaccines (Seqirus) and specialty biologics reduces reliance on any single franchise. Successful launches and differentiated vaccine capacity expansion underpin sustainable revenue channels and create multiple growth levers across geographies for medium-term resilience.
Stable Balance Sheet With Moderate LeverageA moderate debt-to-equity ratio, solid equity base and a healthy ROE reflect financial flexibility. This balance-sheet strength supports continued capital returns, execution of transformation programs and the ability to absorb one-offs without constraining operational investment over the coming months.
Bears Say
Large Impairments And Restructuring CostsMaterial noncash impairments and significant restructuring charges materially depress reported earnings and create earnings volatility. These write-downs reflect asset re-assessment and will weigh on FY26 reported NPAT, complicating near-term performance comparisons and masking underlying operations.
Product- And Market-specific HeadwindsReimbursement changes, government policy enforcement and generic entrants are structural threats to previously stable revenue streams. Sustained pressure on immunoglobulins, albumin in China and iron products can reduce medium-term sales and margin contribution unless offset by new commercial gains or portfolio shifts.
Reliance On Temporary Reimbursement And Looming LOEGrowth tied to temporary reimbursement programs and imminent patent expiries creates cliff risk. With Velphoro's TDAPA set to lapse and Injectafer LOE approaching, CSL faces likely revenue pressure in nephrology/iron franchises that must be offset by new product uptake or pricing improvements.
CSL News
CSLLY FAQ
What was CSL Limited’s price range in the past 12 months?
CSL Limited lowest stock price was $23.68 and its highest was $44.53 in the past 12 months.
What is CSL Limited’s market cap?
CSL Limited’s market cap is $47.50B.
When is CSL Limited’s upcoming earnings report date?
CSL Limited’s upcoming earnings report date is Aug 18, 2026 which is in 125 days.
How were CSL Limited’s earnings last quarter?
CSL Limited released its earnings results on Feb 10, 2026. The company reported $0.208 earnings per share for the quarter, beating the consensus estimate of N/A by $0.208.
Is CSL Limited overvalued?
According to Wall Street analysts CSL Limited’s price is currently Overvalued.
Does CSL Limited pay dividends?
CSL Limited pays a Semiannually dividend of $0.76 which represents an annual dividend yield of 2.33%. See more information on CSL Limited dividends here
What is CSL Limited’s EPS estimate?
CSL Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CSL Limited have?
CSL Limited has 1,941,275,900 shares outstanding.
What happened to CSL Limited’s price movement after its last earnings report?
CSL Limited reported an EPS of $0.208 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.342%.
Which hedge fund is a major shareholder of CSL Limited?
Currently, no hedge funds are holding shares in CSLLY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CSL Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
CSLLY Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 66.1K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.06%
12-Months-Change
Fundamentals
Return on Equity
7.56%
Trailing 12-Months
Asset Growth
-1.42%
Trailing 12-Months
Company Description
CSL Limited
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
CSLLY Company Deck
CSLLY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: solid cash generation, strong specialty product launches (HEMGENIX, ANDEMBRY), Seqirus market-share gains and meaningful progress on a large transformation program were balanced against meaningful near-term headwinds — including revenue declines, large noncash impairments (~$1.1bn), product and market-specific pressures (Ig Medicare Part D impact, albumin policy impact in China, iron generics, and impending reimbursement changes for Velphoro). Management maintained guidance, expanded capital returns, and outlined concrete remediation actions, but several challenges will weigh on reported earnings in the near term.View all CSLLY earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---